Homepage

ABOUT US

Our Leadership

Our Leadership team is composed of seasoned professionals with a strong expertise in the orphan diseases and gene therapy field.

Our Board Members

Meet Vivet’s Board of Directors

Our Investors

Vivet is a private company with strong and committed investors.

Our Partners

Vivet is working with key and reliable long-term partners.

PIPELINE

PROGRAMS

INDICATION / TARGET

RESEARCH

POC

IND ENABLING

PHASE 1/2

PHASE 3

PARTNER

VTX-801

Wilson’s disease

VTX-801 is an AAV-based gene therapy for Wilson’s disease. VTX-801 contains a corrective version of the ATP7B gene, which is malfunctioning in patients affected with Wilson’s disease, and is currently under clinical evaluation in a Phase 1/2 clinical safety and efficacy study (GATEWAY) with a 12-week readout. VTX-801 received US and EU Orphan Drug Designation (ODD).

VTX-802

PFIC 2

VTX-802 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 2. It delivers a codon-optimized version of the BSEP gene to the liver and is currently under preclinical testing.

VTX-803

PFIC 3

VTX-803 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 3. It delivers a codon-optimized version of the MDR3 gene to the liver and is currently under preclinical testing/IND enabling studies. VTX-803 received US and EU Orphan Drug Designation (ODD).

VTX-804

Citrullinemia Type 1

VTX-804 is an AAV-based gene therapy for patients affected by Citrullinemia Type 1. It delivers a codon-optimized version of the ASS1 gene to the liver and is currently under preclinical testing.

VTX-805

Undisclosed

Undisclosed.

VTX-PSM

Sustained Expression

VTX-PSM is a non-integrative viral-based technology aimed to allow sustainability of expression in growing organs and tissues. It allows, without integration into the genome, to replicate the transgene during the mitosis. It is currently under preclinical testing.

VTX-PID

NAbs depletion

VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy.

OUR INVESTORS

Strong and Committed Investors

Vivet Therapeutics has investors from both sides of the ocean, bringing strong support, network and long-term commitment.

5

gene therapy Programs

2

innovation Technologica Platforms

26

dedicated Employees

20

years of cumulated Experience

NEWS

EVENTS

Contact Us
VIVET THERAPEUTICS

  • 80 Boulevard Haussmann
    75008 Paris, FRANCE
  • Av. de Pío XII, 55
    31008 Pamplona Spain
  • info@vivet-therapeutics.com